REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of One Nitrogen And Five Carbon Atoms > Piperidines > Additional Ring Containing > The Additional Ring Is One Of The Cyclos In A Polycyclo Ring System The Additional Ring Is One Of The Cyclos In A Polycyclo Ring SystemThe Additional Ring Is One Of The Cyclos In A Polycyclo Ring System patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027187 - Hydroxy-tetrahydro-naphthalenylurea derivatives This invention relates to hydroxy-tetrahydro-naphthalenylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The hydroxy-tetrahydro-naphthalenylurea derivatives of the present invention have an excellent activity as VR1 antagonist and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the ... 11/16/06 - 20060258705 - Process for making crystalline donepezil hydrochloride monohydrate Solvent mediated polymorphic transformations of crystalline donepezil hydrochloride monohydrate are reduced by using a C5-C8 hydrocarbon as a protecting liquid. ... 10/26/06 - 20060241142 - Naphthamide derivatives and their use wherein R1, R2, R3, R4, m and n are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same. ... 08/17/06 - 20060183776 - Liquid dosage formulations of donepezil The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome, ... 07/27/06 - 20060167051 - Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride The present invention relates to crystalline non-solvated 1-(4-2-piperidinylethoxy)phenoxy)-2-(4-methane-sulfonylphenyl)-6-hydroxynaphthalene hydrochloride, useful as a selective estrogen receptor modulator. ... 07/20/06 - 20060160852 - Composition containing anti-dementia drug An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on the dementia, and also gives excellent compliance. Another object of the present ... 07/13/06 - 20060154965 - Tetralin and indane derivatives and uses thereof wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I. ... 06/29/06 - 20060142338 - 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases In its many embodiments, the present invention provides a novel class of compounds as inhibitors of type 3 17β-hydroxysteroid dehydrogenase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, ... 06/08/06 - 20060122227 - Process for alkylating secondary amines and the use in donepezil preparation thereof The present invention relates to an improved process of alkylating secondary amines, more particularly of alkylating compounds having amino piperidinic group, which are useful as donepezil intermediates, wherein an alcohol serves as reaction facilitator thus enabling to obtain donepezil and salts thereof in high quality and yield. The present invention ... 06/08/06 - 20060122226 - Crystalline forms of donepezil base Novel crystalline forms of Donepezil base, processes for producing same, pharmaceutical compositions containing same and methods of treatment utilizing same are disclosed. ... 04/20/06 - 20060084680 - Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation. ... 03/30/06 - 20060069125 - Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride The present invention provides a crystalline donepezil maleate, which is used as an intermediate in the preparation of donepezil hydrochloride. Also provided are novel processes for producing same in substantially pure form and a process for producing pharmaceutically pure amorphous donepezil hydrochloride therefrom. ... 03/16/06 - 20060058352 - Piperidine amine compounds and their use Compounds having the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, R6, R7 and Ar are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same. ... 02/02/06 - 20060025446 - Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders optically active enantiomers, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions containing such compounds or salts, and processes for their preparation. The subject invention also provides methods of alleviating symptoms of neurologic, autoimmune, and inflammatory disorders caused by the presence of reactive oxygen species, methods of preventing oxidation of lipids, ... 12/29/05 - 20050288330 - Process for producing a polymorphic form of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) The present invention discloses a novel, stable polymorph of 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl]methyl piperidine hydrochloride commonly known as Donepezil hydrochloride. Further the present invention discloses a process for producing Donepezil HCl amorphous and it's polymorph Form (VI). ... 12/08/05 - 20050272775 - Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (donepezil hydrochloride) and a process for producing thereof The present invention discloses a novel, stable polymorph of 1-benzyl-4[(5,6-dimethoxy-1-indanone)-2-yl]methyl piperidine hydrochloride commonly known as Donepezil hydrochloride. Further the present invention discloses a process for producing Donepezil HCl amorphous and its polymorph Form (VI). ... 12/01/05 - 20050267152 - Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders for treating disorders mediated by GlyT1, wherein R1—R9 are as in the description. ... 11/10/05 - 20050250812 - Methods for treating lewy body dementia The invention describes novel methods for treating and preventing dementia caused by vascular diseases; dementia associated with Parkinson's disease; Lewy Body dementia; AIDS dementia; mild cognitive impairments; age-associated memory impairments; cognitive impairments and/or dementia associated with neurologic and/or psychiatric conditions, including epilepsy, brain tumors, brain lesions, multiple sclerosis, Down's syndrome, ... 11/10/05 - 20050250811 - Pleuromutilin derivatives as antimicrobbials R6 is hydrogen, hydroxy or (C2-12)acyloxy, and their use as antimicrobials ... 10/27/05 - 20050239839 - Adamantylglycine-based inhibitors of dipeptidyl peptidase iv and methods Y is CH, CH2, CHF, CF2, O, S, SO, or SO2; and A is adamantyl. Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds. ... 10/27/05 - 20050239838 - Methods of treating sleep disorders The invention relates to novel antihistamines and methods of modulating sleep by administering a doxepin analog or a pharmaceutically effective salt thereof. ... 10/27/05 - 20050239837 - Process for production of highly pure donepezil hydrochloride Disclosed is a process for production of highly pure donepezil hydrochloride in the form of polymorph I that does not involve the isolation of donepezil base. The disclosed process involves intramolecular cyclization of N-benzyl-2-(3,4-dimethoxybenzyl)-3-(4-piperidine)propionic acid followed by treatment with HCl. ... 10/27/05 - 20050239836 - Substituted hydroxyethylamine aspartyl protease inhibitors The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein. ... 10/13/05 - 20050228021 - Adamantylglycine-based inhibitors of dipeptidyl peptidase iv and methods Y is CH, CH2, CHF, CF2, O, S, SO, or SO2; and A is adamantyl. Further provided are methods of using such compounds for the treatment of diabetes and related diseases, and to pharmaceutical compositions containing such compounds. ... 10/13/05 - 20050228020 - Beta secretase inhibitors wherein Ar is an aromatic group; X is a divalent group selected from —O—, —S—, —CO—, —SO—, —SO2—, —NR8—, CONR8—, —SO2NR8—, and —COO— (wherein R8 is hydrogen, etc.), a divalent C1-6 aliphatic hydrocarbon group which may contain one or two of these divalent groups, or a bond; Y is a ... 10/13/05 - 20050228019 - Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors The present invention relates to a method for enhancing the physiological and therapeutic effects of an AMPA receptor potentiator in an animal by co-administration of an acetylcholinesterase inhibitor with the potentiator. Also disclosed is a method for treating a cognitive disorder in an animal by co-administration of an AMPA receptor ... 10/06/05 - 20050222208 - Novel process for amorphous form of donepezil hydrochloride The present invention provides a novel process for the preparation of amorphous form of donepezil hydrochloride. ... 09/29/05 - 20050215592 - Methods for assessing, improving, or maintaining urogenital health in postmenopausal woman This invention relates to methods and kits useful for improving or maintaining urogenital health using an estrogen agonist/antagonist. The methods of treatment are effective for improving or maintaining urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration. This invention also relates to methods of ... 09/29/05 - 20050215591 - Novel crystalline forms of donepezil hydrochloride The present invention provides novel crystalline forms of donepezil hydrochloride, processes for their preparation and pharmaceutical compositions containing them. ... 09/22/05 - 20050209281 - Method of producing polymorphic crystals of donepezil hydrochloride The present invention provides a simple method of producing polymorphic crystal (III), which has high safety to environment and the bodies of operators; is gentle to environment; and can produce at low costs; and has a high refining effect. It is a method of producing polymorphic crystal (III) of donepezil ... 07/07/05 - 20050148632 - Therapeutic agent for intestinal diseases and visceral pain The present invention relates to a therapeutic agent for irritable bowel syndrome of diarrhea type, ulcerative colitis, visceral pain or abdominal pain, which contains a compound of the following formula and which has 5-HT7 receptor antagonistic effect or an analogue thereof; and this therapeutic agent has an excellent therapeutic effect ... 06/16/05 - 20050131023 - Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori A method of preventing or treating diseases mediated by Helicobacter pylori, comprising administering to a subject in need of such treatment an effective amount of pleuromutilin. ... ### FreshPatents.com Support |